Fastest Ever Robotics-Driven COVID-19 Mass Testing Platform Gives 99% Accurate Results
By HospiMedica International staff writers Posted on 01 Dec 2020 |
Image: Fastest Ever Robotics-Driven COVID-19 Mass Testing Platform Gives 99% Accurate Results (Photo courtesy of Salient Bio)
A new robotics-driven COVID-19 mass testing platform that has been rolled out is up to three times faster than competitors for mass testing and aims to provide affordable, effective and easy-to-access pre-emptive diagnostic solutions for a range of medical conditions that facilitate early intervention and improve overall health outcomes.
Salient Bio (London, UK) has announced the commercial launch of its robotics-driven COVID-19 mass testing platform which facilitates COVID-secure environments at a quicker and more cost effective rate than the closest approved competitor, with a same day results notification process and a very cost effective per unit price for businesses conducting mass testing. The platform is reagent agnostic, meaning that disruption in supply chains can be mitigated by a shift to different reagent suppliers without it calling for wholesale infrastructure change at Salient’s labs, therefore limiting disruption and costs. Its accuracy, fast delivery and cost effectiveness make Salient Bio’s modular diagnostics platform ideal for sectors that require a safe environment for regular human contact, such as logistics, facilities management, education and manufacturing.
“With the rollout of vaccines likely to be staggered, rapid and accurate mass testing will play a vital role in the coming months in our immediate fight against COVID,” said Dr. Miles Priestman, Co-founder of Salient Bio. “Yet existing diagnostic labs often involve error prone manual processes – there is a huge opportunity to reinvent how they operate from the ground up. Using state of the art robotics and bespoke software development we hope to do just this, bringing significant cost and operational efficiency gains to help bring diagnostic labs fully into the 21st century.”
Related Links:
Salient Bio
Salient Bio (London, UK) has announced the commercial launch of its robotics-driven COVID-19 mass testing platform which facilitates COVID-secure environments at a quicker and more cost effective rate than the closest approved competitor, with a same day results notification process and a very cost effective per unit price for businesses conducting mass testing. The platform is reagent agnostic, meaning that disruption in supply chains can be mitigated by a shift to different reagent suppliers without it calling for wholesale infrastructure change at Salient’s labs, therefore limiting disruption and costs. Its accuracy, fast delivery and cost effectiveness make Salient Bio’s modular diagnostics platform ideal for sectors that require a safe environment for regular human contact, such as logistics, facilities management, education and manufacturing.
“With the rollout of vaccines likely to be staggered, rapid and accurate mass testing will play a vital role in the coming months in our immediate fight against COVID,” said Dr. Miles Priestman, Co-founder of Salient Bio. “Yet existing diagnostic labs often involve error prone manual processes – there is a huge opportunity to reinvent how they operate from the ground up. Using state of the art robotics and bespoke software development we hope to do just this, bringing significant cost and operational efficiency gains to help bring diagnostic labs fully into the 21st century.”
Related Links:
Salient Bio
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans